Li, C., Tian, Y., Zheng, Y., Yuan, F., Shi, Z., Yang, L., Chen, H., Jiang, L., Wang, X., Zhao, P., Zhang, B., Wang, Z., Zhao, Q., Dong, J., Lian, C., Xu, S., Zhang, A., Zheng, Z., Wang, K., Dang, C., Wu, D., Chen, J., Xue, Y., Liang, B., Cheng, X., Wang, Q., Chen, L., Xia, T., Liu, H., Xu, D., Zhuang, J., Wu, T., Zhao, X., Wu, W., Wang, H., Peng, J., Hou, Z., Zheng, R., Chen, Y., Yin, K., Zhu, Z. (2025). Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05). Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00795